Central Nervous System Therapeutics Global Market Report 2025

Description

Central nervous system (CNS) therapeutics refers to drugs and treatments developed to manage and treat disorders of the brain and spinal cord. These therapies target conditions such as depression, epilepsy, Parkinson's disease, and multiple sclerosis, aiming to restore neurological function, alleviate symptoms, and enhance patients' quality of life. CNS therapeutics may include pharmaceuticals, biologics, and advanced neurotechnological interventions.

The primary drug classes in CNS therapeutics include anesthetics, anticonvulsants, antiemetics, CNS stimulants, pain relievers, and others. Anesthetics are medications that block pain or induce unconsciousness during medical procedures. These drugs address a variety of diseases, including neurovascular disorders, mental health conditions, degenerative and genetic disorders, substance abuse, autoimmune and inflammatory diseases, CNS trauma, infectious diseases, and CNS cancers. They are distributed through channels such as hospital and retail pharmacies and are applied across hospitals, clinics, homecare, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The central nervous system therapeutics market research report is one of a series of new reports from The Business Research Company that provides central nervous system therapeutics market statistics, including central nervous system therapeutics industry global market size, regional shares, competitors with a central nervous system therapeutics market share, central nervous system therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. This central nervous system therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $123.53 billion in 2024 to $134.99 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising prevalence of neurological disorders, increasing awareness of mental health issues, expansion of research and development activities, growing demand for personalized medicine, and the facilitation of trade agreements supporting the CNS therapeutics market.

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $190.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the rising prevalence of central nervous system (CNS) disorders, increased focus on developing novel therapeutics, growing incidence of conditions such as Alzheimer's disease, an expanding aging population, and higher demand for effective treatments. Major trends during this period include the use of artificial intelligence in diagnostics, advancements in antidepressant drug development, innovations in drug delivery systems, progress in neurology research, and identification of novel biomarkers.

The increasing prevalence of mental health disorders is expected to propel the growth of the central nervous system (CNS) therapeutics market going forward. Mental health disorders encompass a range of conditions affecting thinking, feeling, behavior, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. Rising exposure to chronic stress contributes to these disorders by disrupting emotional regulation, weakening coping mechanisms, and increasing susceptibility to anxiety, depression, and burnout. CNS therapeutics address these disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, the Bristol City Council, a UK-based local government authority, reported that 66,815 patients aged 18 and over were recorded on GP practice depression registers in Bristol in 2022/23, representing a 6.0% increase from 2021/22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system (CNS) therapeutics market.

Key companies in the central nervous system (CNS) therapeutics market are focusing on innovative approaches such as capsid engineering to enhance targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration in neurological disorders. Capsid engineering involves optimizing the protein shell of viral vectors, typically adeno-associated viruses (AAVs), for gene therapy. For example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel AAV for CNS delivery using its ALIGATER platform. The vector demonstrated 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus compared to AAV9 at the same dose, with equivalent expression achieved at one-fifth of the dose. It also reduced off-target expression in peripheral organs while maintaining a favorable safety profile, highlighting its potential to improve CNS gene therapy outcomes with precision and lower systemic risk.

In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount to expand its neuroscience portfolio, strengthen its position in the CNS market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company specializing in CNS therapeutics.

Major players in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the central nervous system therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central nervous system therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Anesthetics; Anticonvulsants; Antiemetics; Central Nervous System (CNS) Stimulants; Pain Relievers; Other Drug Classes
2) By Disease: Neurovascular Diseases; Mental Health; Degenerative Disorders; Genetic Diseases; Substance Abuse Disorders; Autoimmune And Inflammatory Diseases; Central Nervous System (CNS) Trauma; Infectious Diseases; Central Nervous System (CNS) Cancer; Other Diseases
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
4) By Application: Hospital; Clinic; Homecare; Other Applications
Subsegments:
1) By Anesthetics: General Anesthetics; Local Anesthetics; Dissociative Anesthetics; Inhalation Anesthetics; Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers; GABA Enhancers; Calcium Channel Blockers; SV2A Modulators; Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists; Dopamine Antagonists; Neurokinin-1 (NK1) Receptor Antagonists; Antihistamines; Cannabinoids
4) By Central Nervous System (CNS) Stimulants: Amphetamines; Methylphenidates; Modafinil and Armodafinil; Caffeine-Based Stimulants; Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Antidepressants for Neuropathic Pain; Anticonvulsants for Pain Relief; Topical Agents
6) By Other Drug Classes: Antipsychotics; Antidepressants; Muscle Relaxants; Sedatives and Hypnotics; Neuroprotective Agents
Companies Mentioned: Biogen Inc.; Otsuka Pharmaceutical Co Ltd.; UCB S.A.; Jazz Pharmaceuticals plc; Supernus Pharmaceuticals Inc.; Biohaven Ltd.; Acadia Pharmaceuticals Inc.; Neumora Therapeutics Inc.; Cerevel Therapeutics LLC; Axsome Therapeutics Inc.; TauRx Therapeutics Ltd.; Kyverna Therapeutics Inc.; Immunic Inc.; LEXEO Therapeutics Inc.; Autobahn Therapeutics; BrainStorm Cell Therapeutics Inc.; Progentos Therapeutics Inc.; Tonix Pharmaceuticals Holding Corp.; Neuroplast B.V.; Assertio Holdings Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37720

1. Executive Summary

2. Central Nervous System Therapeutics Market Characteristics

3. Central Nervous System Therapeutics Market Trends And Strategies

4. Central Nervous System Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Central Nervous System Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Central Nervous System Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Central Nervous System Therapeutics Market Growth Rate Analysis
5.4. Global Central Nervous System Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Central Nervous System Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Central Nervous System Therapeutics Total Addressable Market (TAM)

6. Central Nervous System Therapeutics Market Segmentation

6.1. Global Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anesthetics
Anticonvulsants
Antiemetics
Central Nervous System (CNS) Stimulants
Pain Relievers
Other Drug Classes
6.2. Global Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neurovascular Diseases
Mental Health
Degenerative Disorders
Genetic Diseases
Substance Abuse Disorders
Autoimmune And Inflammatory Diseases
Central Nervous System (CNS) Trauma
Infectious Diseases
Central Nervous System (CNS) Cancer
Other Diseases
6.3. Global Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channel
6.4. Global Central Nervous System Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinic
Homecare
Other Applications
6.5. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
General Anesthetics
Local Anesthetics
Dissociative Anesthetics
Inhalation Anesthetics
Intravenous Anesthetics
6.6. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sodium Channel Blockers
GABA Enhancers
Calcium Channel Blockers
SV2A Modulators
Mixed Mechanism Agents
6.7. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Antiemetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Serotonin 5-HT3 Antagonists
Dopamine Antagonists
Neurokinin-1 NK1 Receptor Antagonists
Antihistamines
Cannabinoids
6.8. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Central Nervous System (CNS) Stimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphetamines
Methylphenidates
Modafinil And Armodafinil
Caffeine Based Stimulants
Xanthine Derivatives
6.9. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Pain Relievers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Opioid Analgesics
Non Steroidal AntiInflammatory Drugs NSAIDs
Antidepressants For NeuropathicPain
Anticonvulsants For Pain Relief
Topical Agents
6.10. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antipsychotics
Antidepressants
Muscle Relaxants
Sedatives And Hypnotics
Neuroprotective Agents

7. Central Nervous System Therapeutics Market Regional And Country Analysis

7.1. Global Central Nervous System Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Central Nervous System Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Central Nervous System Therapeutics Market

8.1. Asia-Pacific Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Central Nervous System Therapeutics Market

9.1. China Central Nervous System Therapeutics Market Overview
9.2. China Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Central Nervous System Therapeutics Market

10.1. India Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Central Nervous System Therapeutics Market

11.1. Japan Central Nervous System Therapeutics Market Overview
11.2. Japan Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Central Nervous System Therapeutics Market

12.1. Australia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Central Nervous System Therapeutics Market

13.1. Indonesia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Central Nervous System Therapeutics Market

14.1. South Korea Central Nervous System Therapeutics Market Overview
14.2. South Korea Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Central Nervous System Therapeutics Market

15.1. Western Europe Central Nervous System Therapeutics Market Overview
15.2. Western Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Central Nervous System Therapeutics Market

16.1. UK Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Central Nervous System Therapeutics Market

17.1. Germany Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Central Nervous System Therapeutics Market

18.1. France Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Central Nervous System Therapeutics Market

19.1. Italy Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Central Nervous System Therapeutics Market

20.1. Spain Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Central Nervous System Therapeutics Market

21.1. Eastern Europe Central Nervous System Therapeutics Market Overview
21.2. Eastern Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Central Nervous System Therapeutics Market

22.1. Russia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Central Nervous System Therapeutics Market

23.1. North America Central Nervous System Therapeutics Market Overview
23.2. North America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Central Nervous System Therapeutics Market

24.1. USA Central Nervous System Therapeutics Market Overview
24.2. USA Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Central Nervous System Therapeutics Market

25.1. Canada Central Nervous System Therapeutics Market Overview
25.2. Canada Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Central Nervous System Therapeutics Market

26.1. South America Central Nervous System Therapeutics Market Overview
26.2. South America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Central Nervous System Therapeutics Market

27.1. Brazil Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Central Nervous System Therapeutics Market

28.1. Middle East Central Nervous System Therapeutics Market Overview
28.2. Middle East Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Central Nervous System Therapeutics Market

29.1. Africa Central Nervous System Therapeutics Market Overview
29.2. Africa Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Central Nervous System Therapeutics Market Competitive Landscape And Company Profiles

30.1. Central Nervous System Therapeutics Market Competitive Landscape
30.2. Central Nervous System Therapeutics Market Company Profiles
- 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Jazz Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Supernus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Central Nervous System Therapeutics Market Other Major And Innovative Companies

31.1. Biohaven Ltd.
31.2. Acadia Pharmaceuticals Inc.
31.3. Neumora Therapeutics Inc.
31.4. Cerevel Therapeutics LLC
31.5. Axsome Therapeutics Inc.
31.6. TauRx Therapeutics Ltd.
31.7. Kyverna Therapeutics Inc.
31.8. Immunic Inc.
31.9. LEXEO Therapeutics Inc.
31.10. Autobahn Therapeutics
31.11. BrainStorm Cell Therapeutics Inc.
31.12. Progentos Therapeutics Inc.
31.13. Tonix Pharmaceuticals Holding Corp.
31.14. Neuroplast B.V.
31.15. Assertio Holdings Inc.

32. Global Central Nervous System Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System Therapeutics Market

34. Recent Developments In The Central Nervous System Therapeutics Market

35. Central Nervous System Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Central Nervous System Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Central Nervous System Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Central Nervous System Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer